Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab neoadjuvant phase II trial in resectable MSI-H/dMMR duodenal adenocarcinoma
ChiCTR2500098957Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in duodenal adenocarcinoma (DA), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Imaging-based tumor response to treatment and Tumor pathological regression grade. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
duodenal adenocarcinoma (DA)
Beyond the preview
Go deeper on ChiCTR2500098957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098957.